Healthcare
PsyBio Therapeutics Corp.(PSYBF)
Live Price
Offline$0.00001
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +58.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PsyBio Therapeutics Corp. (PSYBF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +58.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +58.0%, free cash flow +50.5% with operating margin 0.0% and ROIC 328.6%. Stock Foundry combines PSYBF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Jun 30, 2023, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +58.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2023 Jun 30, 2023 | โ | +0.0% | +0.0% | +0.0% |
2023 Mar 31, 2023 | โ | +0.0% | +0.0% | +0.0% |
2022 Dec 31, 2022 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSYBF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PSYBF Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PSYBF and SPY.
Company Overview
PsyBio Therapeutics Corp.
Other OTC
PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. The company is headquartered in Coconut Creek, Florida.
- Leadership
- Evan Mike Levine
- IPO Date
- Apr 23, 2021
- Employees
- 4
- Street Address
- 4400 West Sample Road
- Mailing
- Coconut Creek, FL, 33073
- Region
- Coconut Creek, FL, US
- Reporting Currency
- USD
- Investor Line
- 513 449 9585
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +58.0%
- Free Cash Flow
- +50.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -867.3%
- ROIC
- 328.6%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.